Document is current
Any future updates will be listed below
-
Authors
Walton, Andrew H.
Mazer, Monty B.
Remy, Kenneth E.
Osborne, Dale F.
Davitt, Ethan B.
Griffith, Thomas S.
Gould, Robert W.
Badovinac, Vladimir P.
Brakenridge, Scott C.
Drewry, Anne M.
Ungaro, Ricardo F.
Rocha, Ivanna L.
Loftus, Tyler J.
Efron, Philip A.
Moldawer, Lyle L.
Caldwell, Charles C.
Hotchkiss, Richard S.
-
Funding
Funding for this research was provided by:
National Institute of General Medical Sciences (R01 GM-139046, R01 GM-139046, R01 GM-139046, R01 GM-139046, R01 GM-139046, R01 GM-139046, R01 GM-139046, R01 GM-139046, R01 GM-139046, R01 GM-139046, R01 GM-139046, R01 GM-139046, R01 GM-139046, R01 GM-139046, R01 GM-139046, R01 GM-139046, R01 GM-139046)
National Institute of General Medical Sciences,United States (R35 GM-140881, R35 GM-134880, R35 GM-134880, R01 GM-149657, RM1-GM-139690, RM1-GM-139690, R35 GM-126928)
U.S. Department of Defense (G102983-6263608307-1)
U.S. Department of Veterans Affairs (IK6BX006192)
- License Information
-
More Information
Article History
Received: 19 August 2024
Accepted: 25 February 2025
First Online: 18 April 2025
Declaration
:
: MBM, and KER are members of Immune Functional Diagnostics, LLC and receive no direct financial compensation. Immune Functional Diagnostics, LLC is developing predictive metrics in critical illness and this technology (provisional patent application 63/521,817) is evaluated in this research. SCB, LLM, RSH, and the University of Florida may receive royalty income based on a technology developed by SCB and others and licensed by Washington University in St. Louis to IFDx LLC. That technology is evaluated in this research. CCC and the University of Cincinnati may receive royalty income based on a technology developed by CCC and others and licensed by Washington University in St. Louis to IFDx LLC. That technology is evaluated in this research.
